Published in Cancer Weekly, November 13th, 2001
In September (2001) the Committee for Proprietary Medicinal Products of the European Medicines Evaluation Agency adopted a positive opinion on a variation to the manufacturing process for Thyrogen, which was necessary for commercial introduction of the product. Thyrogen was approved for marketing in Europe last year and has been available on a named-patient basis since...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.